Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Adults.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 24 Mar 2012 Official title amended as reported by European Clinical Trials Database.
- 17 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.